Pharma major Dr Reddy’s Laboratories and Argenta,a UK-based contract research firm,have entered in to an agreement for collaboration in drug discovery.
The collaboration will be in the area of pain and inflammation,according to Argenta.
Commercial terms of the agreement were not disclosed. Argenta will apply its integrated drug discovery platform and expertise on multiple Dr Reddy’s discovery targets in pain and inflammation. The aim of the collaboration is to deliver high quality development candidates to support Dr Reddy’s research efforts for proprietary products.
“We are excited to be working with Dr Reddy’s in identifying novel and differentiated drug candidates for multiple targets meeting unmet clinical needs in pain and inflammation,” said John Montana,Managing Director,Argenta.
Four years ago,the Indian company had announced a similar agreement with Argenta in the area of respiratory treatment,including chronic obstructive pulmonary disease and severe asthma.